Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bosutinib or bosutinib+ aprepitant · 1 trial · 1 indication
AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.
Cmax is the peak concentration.
| Arm | Type | Description |
|---|---|---|
| Healthy volunteers | OTHER | Healthy volunteers taking a single dose of bosutinib and a single dose of bosutinib plus aprepitant in random order |
| Name | Type | Description |
|---|---|---|
| bosutinib or bosutinib + aprepitant | DRUG | Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg) |
Inclusion Criteria: * Healthy male and/or female subjects with an informed consent document signed and dated by the subject. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neur...
Bosutinib is a small molecule kinase inhibitor developed by Pfizer, Inc. (ticker PFE). It is being studied in a Phase 1 drug interaction trial with aprepitant in healthy volunteers. The trial, NCT02058277, has been completed and enrolled 20 participants. Bosutinib is an investigational agent and has not been approved for the studied combination.
Bosutinib targets ABL1, BCR, HCK, LYN, and SRC kinases. It is classified as an inhibitor of these targets. This activity profile is relevant to its mechanism of action as a small molecule therapeutic.
Bosutinib is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the sponsor of the clinical trial evaluating bosutinib in combination with aprepitant.
Bosutinib is in Phase 1 clinical development. The only listed trial is a Phase 1 drug interaction study between bosutinib and aprepitant in healthy volunteers. This trial has been completed. Bosutinib is investigational and has not been approved for the studied combination.
Bosutinib has been studied in one clinical trial: NCT02058277, titled "A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers." This Phase 1 trial was completed, enrolled 20 healthy volunteers, and was conducted in the United States. It was an uncontrolled, non-randomized study.